In the claims:

Please amend claim 13 as follows:

1. (Previously amended) Micronized powder particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronized particles have a diameter of from 0.01 to 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.

2. (Previously amended) Colistin sulphomethate sodium for the use as claimed in Claim 1 wherein the micronized powder is mixed with a carrier.

3. (Original) Colistin sulphomethate sodium for the use as claimed in Claim 2 wherein the carrier is lactose.

4. (Previously amended) A composition comprising micronized colistin sulphomethate sodium as defined in Claim 1 and a carrier, in the absence of free liquid.

C1

5. (Original) A composition as claimed in Claim 4 wherein the carrier is lactose.

6. (Previously amended) A composition as claimed in Claim 4 wherein the ratio of colistin sulphomethate sodium to carrier is from 5:1 to 1:2 by weight.

7. (Previously amended) A composition as claimed in Claim 4 wherein the ratio of colistin sulphomethate sodium to carrier is from 4:1 to 1:1 by weight.

8. (Previously amended) The composition as claimed in Claim 4 wherein at least 50% by volume of the carrier particles have an effective particle size in the range of 30-150 micrometers.

9. (Previously amended) A composition as claimed in Claim 4 wherein at least 50% by volume of the micronized colistin sulphomethate sodium has a particle diameter of from 0.01 to 8 micrometers.

10. (Previously amended) A composition as claimed in Claim 4 wherein at least 25% of the particles of micronized colistin sulphomethate sodium have a diameter of from 0.01 to 6 micrometers.

11. (Previously amended) A composition as claimed in Claim 4 wherein the micronized colistin sulphomethate sodium is prepared in the desired particle size range using a fluid energy mill.

12. (Previously amended) A process for the preparation of a composition as claimed in Claim 4 which comprises mixing micronized colistin sulphomethate sodium and a carrier.

13. (Twice amended) A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising micronized powdered colistin sulphomethate sodium wherein at least 90% by volume of the particles have a diameter from 0.01 to [less than]10 micrometers or a composition according to Claim 4 and a container, said dosage having a content of below 10 wt % water.

14. (Original) A pharmaceutical dosage form according to Claim 13 wherein the container is a hard gelatin capsule.

C1 cont.

15. (Previously amended) A capsule containing micronized colistin sulphomethate sodium wherein at least 90% by volume of the micronized powdered particles have a diameter of from 0.01 to 10 micrometers.

16. (Original) A capsule as claimed in Claim 15 containing from 10 to 200 milligrams of micronised colistin sulphomethate sodium.

17. (Original) A capsule as claimed in Claim 15 containing from 30 to 150 milligrams of micronised colistin sulphomethate sodium.

18. (Previously amended) A capsule as claimed in Claim 15 further comprising a carrier.

19. (Previously amended) A capsule as claimed in Claim 15 when the carrier is lactose.

20. (Previously amended) A capsule according to Claim 15 which is opaque.

21. (Previously amended) A capsule according to Claim 15 packed in an opaque container.

22. (Cancelled) A capsule containing micronised colistin sulphomethate sodium when the micronised particles have a diameter of less than 10 micrometers, in unit dosage form.

23. (Previously amended) A capsule according to Claim 15 which additionally comprises a micronized bronchodilatory drug.

24. (Original) A capsule according to Claim 23 wherein the bronchodilatory drug is salbutamol.

25. (Previously amended) A capsule according to Claim 23 which comprises from 50 to 150 milligrams of colistin sulphomethate sodium and from 1 to 250 micrograms of bronchodilatory drug.

C1 cancel

26. (Cancelled) Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.

27. (Cancelled) Colistin sulphomethate sodium for the use as claimed in Claim 26 wherein the micronised powder is mixed with a carrier.

28. (Cancelled) Colistin sulphomethate sodium for the use as claimed in Claim 27 wherein the carrier is lactose.

29. (Previously added) A composition according to Claim 4 packed in an opaque container.